Anil Kapoor

About

Dr. Anil Kapoor, MD, FRCSC
Professor of Surgery (Urology), McMaster University
Director, Urologic Cancer Centre for Research & Innovation (UCCRI)
Head, Genito-Urinary Oncology Program, Juravinski Cancer Centre
Hamilton, Ontario, Canada
[email protected]



Dr. Anil Kapoor is currently Professor of Surgery (Urology & Oncology) at McMaster University/ St. Joseph’s Hospital in Hamilton, Ontario, Canada. He obtained his MD from Dalhousie University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada and a Diplomate of American Board of Urology. He is certified by the American Society of Transplant Surgeons, having obtained post-graduate training from the Cleveland Clinic Foundation in Renal Transplantation, Reno-Vascular surgery, and GU Oncology.

Dr. Kapoor is current Director of the Urologic Cancer Centre for Research & Innovation (UCCRI) at St. Joseph’s Hamilton, Head of the Genito-Urinary Oncology program at the Juravinski Cancer Centre, Co-Chair of the NCIC Kidney Cancer Disease Group, and Chair of the Kidney Cancer Research Network of Canada (KCRNC). He is a member of the Board of Directors of Kidney Cancer Canada (KCC). He has published over 330 peer-reviewed papers, 12 book chapters and over 200 abstracts in the fields of genito-urinary oncology (prostate cancer and kidney cancer), kidney transplantation, and urologic laparoscopy. He is current Head of the Clinical Trials Group at the McMaster Institute of Urology (MIU) and established the Kidney Cancer Centre at McMaster University in 2009.

Employment

• McMaster University Faculty of Health Sciences

Education

• Dalhousie University MD

Projects & Funding

Projects & funding information is unavailable.

Publications (374)

• Taxifolin Inhibits the Growth of Non-Small-Cell Lung Cancer via Downregulating Genes Displaying Novel and Robust Associations with Immune Evasion Factors
  Cancers 2023 DOI: 10.3390/cancers15194818
  +Save
• Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
  Journal of Clinical Medicine 2023 DOI: 10.3390/jcm12175604
  +Save
• Taxifolin Inhibits Breast Cancer Growth by Facilitating CD8+ T Cell Infiltration and Inducing a Novel Set of Genes including Potential Tumor Suppressor Genes in 1q21.3
  Cancers 2023 DOI: 10.3390/cancers15123203
  +Save
• Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States
  Annals of Epidemiology 2023 DOI: 10.1016/j.annepidem.2023.01.003
  +Save
• Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels
  Cancers 2022 DOI: 10.3390/cancers14112805
  +Save
• Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial
  Radiology 2022 DOI: 10.1148/radiol.211824
  +Save
• Insights of RKIP-Derived Suppression of Prostate Cancer
  Cancers 2021 DOI: 10.3390/cancers13246388
  +Save
• Prognostic and Therapeutic Potential of the OIP5 Network in Papillary Renal Cell Carcinoma
  Cancers 2021 DOI: 10.3390/cancers13174483
  +Save
• Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel Towards Prostate Cancer Relapse
  Genes 2021 DOI: 10.3390/genes12020257
  +Save
• Effective Prediction of Prostate Cancer Recurrence through the IQGAP1 Network
  Cancers 2021 DOI: 10.3390/cancers13030430
  +Save